Occident Group

Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Altavo is a medical device startup focused on creating artificial voice solutions for individuals who have lost their ability to speak due to surgery or disease. By leveraging advanced machine learning and cutting-edge sensor technology, Altavo develops custom, natural-sounding voices that enable voiceless individuals to communicate effectively. The company's innovative approach combines speech recognition and synthesis, significantly enhancing the quality of life for those with speech disorders.

Chipmetrics specializes in the development of test structures, test chips, and wafer concepts tailored for advanced materials and microelectronics manufacturing. The company is recognized for its expertise in characterizing thin film conformality, providing clients with fast and accurate data essential for evaluating various 3D thin film processes and reactors. Its primary product line, the PillarHall test chips, plays a crucial role in facilitating the application of conformal 3D thin films, thereby supporting innovation and efficiency in the manufacturing industry. By focusing on this niche, Chipmetrics aims to enhance the capabilities of its clients in the realm of microelectronics.

ReCatalyst specializes in the development and commercialization of advanced platinum-alloy catalysts for hydrogen fuel cells. The company focuses on creating next-generation nano-catalysts that enhance stability and reduce the amount of platinum needed in each fuel cell system. By optimizing the use of platinum group metals, ReCatalyst enables significant scalability of high-power proton exchange membrane fuel cells. This innovative approach aims to improve the efficiency and affordability of fuel cell technology, positioning the company as a key player in the clean energy sector.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

core sensing breathes new life into machines. The innovative coreIN product line integrates innovative IoT sensor technology into standard mechanical components. This patented technology enables easy implementation and real-time data collection - without complex redesigns. Smart components, smart insights coreIN goes far beyond simple component replacement. The smart components provide valuable real-time data and intelligent analytics that optimize functionality. The robust IoT sensor platform coreNET ensures a seamless connection from the sensor to the cloud. This enables breakthrough products and services with high added value. The patented coreIN technology measures loads directly at the source of potential failures, enabling comprehensive machine insight. Smart sensors with advanced algorithms and AI capabilities accurately analyze machine condition and performance. Successful partnerships for breakthrough innovation Together with our partners, we develop intelligent series products that set new standards. Our customers include well-known companies in various industries, including Roll Forming Machines, Conveyor Belts & Trucks.

Avelo is a manufacturer of diagnostic equipment focused on infectious diseases. The company has developed a non-invasive breath aerosol testing system that allows for rapid detection of multiple lower respiratory tract infections. This innovative product enables primary care providers to conduct quick sample-to-answer tests, providing results within minutes through a streamlined three-step process. By facilitating early diagnosis, Avelo's technology aims to improve patient outcomes through timely antibiotic or antiviral treatment and efficient patient referrals. The company's mission centers on enhancing the speed and accuracy of infectious disease diagnoses to ultimately save lives.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in security software aimed at helping developers identify and address vulnerabilities in their code. The company offers an automated application security testing platform that utilizes coverage-based fuzzing and symbolic code execution to generate attack inputs, thereby facilitating the detection of critical vulnerabilities and crashes. This solution significantly reduces the need for extensive expert knowledge by establishing a continuous testing infrastructure. Code Intelligence serves a diverse clientele, including notable organizations such as Bosch, Deutsche Börse Group, and Deutsche Telekom, ensuring that their software remains secure and reliable.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in security software aimed at helping developers identify and address vulnerabilities in their code. The company offers an automated application security testing platform that utilizes coverage-based fuzzing and symbolic code execution to generate attack inputs, thereby facilitating the detection of critical vulnerabilities and crashes. This solution significantly reduces the need for extensive expert knowledge by establishing a continuous testing infrastructure. Code Intelligence serves a diverse clientele, including notable organizations such as Bosch, Deutsche Börse Group, and Deutsche Telekom, ensuring that their software remains secure and reliable.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

GNA Biosolutions is a molecular technology company located in Martinsried, Germany, specializing in innovative diagnostic devices for detecting and analyzing DNA. Their core technology, Pulse Controlled Amplification, enhances molecular testing by integrating ultrafast nucleic acid amplification with intrinsic sample preparation. This advancement allows for efficient and simplified diagnosis of human pathogens in laboratory settings, as well as on-site applications and Point of Care scenarios. GNA Biosolutions aims to make the benefits of molecular testing accessible to a broader audience, facilitating rapid and accurate results from sample collection to analysis.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that specializes in the development of species-specific therapeutic antibodies for companion animals, particularly dogs. The company focuses on addressing serious diseases in pets and aims to extend its therapeutic offerings to other animal species. Adivo utilizes a fully synthetic, dog-specific drug library to select antibodies with optimal properties through phage display technology. As a spin-off of MorphoSys AG, Adivo benefits from extensive expertise in the development of human therapeutic antibodies, which the team applies to advance veterinary medicine.

InSphero AG specializes in the development of organotypic biological 3D microtissues and microtissue-based assays, aimed at enhancing in vitro testing for drug discovery and toxicity assessment. Founded in 2009 and headquartered in Schlieren, Switzerland, the company provides a variety of products including liver, pancreas, and tumor microtissues, as well as custom-made microtissues and specialized kits. InSphero's 3D cell culture platforms, such as the GravityTRAP ultra-low attachment plate, facilitate the generation and analysis of scaffold-free 3D microtissue spheroids. Their offerings also extend to cytotoxicity assay kits and services for hepatotoxicity testing, cancer research, and stem cell applications. The technology developed by InSphero enables researchers to obtain biologically relevant insights, improving the predictive power of drug testing and reducing reliance on animal testing.

advanceCOR GmbH is a drug development company based in Munich, Germany, specializing in therapeutics and diagnostics for heart and vascular diseases. Founded in 2000, the company focuses on creating personalized treatments and has developed several innovative products. Notable among these is Revacept, a human Fc fusion protein that inhibits the local activation of platelets at vascular injury sites. Additionally, advanceCOR offers COR-2, a recombinant protein that reduces foam cell generation and cholesterol uptake, and COR-3, which targets atherosclerotic plaques while binding to progenitor cells to promote plaque healing. The company’s product pipeline also includes therapies for acute arterial thrombosis, myocardial infarction, stroke, and transient ischemic attack, emphasizing its commitment to addressing serious cardiovascular conditions.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, founded in 2010. It specializes in developing innovative solutions for the treatment and management of glaucoma, a prevalent eye disease. The company's flagship product, Eyemate, is an implantable micro sensor designed for continuous intraocular pressure measurement. This biocompatible device allows for 24-hour monitoring without compromising the patient's vision or overall well-being. By integrating advanced medical technology with information technology, Implandata aims to enhance the efficiency of glaucoma therapy, benefiting patients, their families, and caregivers. The company's focus on addressing unmet needs in glaucoma care positions it as a significant player in the ophthalmic medical device sector.

Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, the company is dedicated to addressing the unmet medical needs of patients globally. Its lead candidate, VS-01, is in the preclinical stage and aims to be the first drug for acute liver disease, with the unique capability of supporting multiple organ function. VS-01 has received Orphan Drug Designation for acute liver failure, highlighting its potential in treating rare conditions. Additionally, Versantis is advancing other products in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent significant opportunities for improving patient outcomes in the field of liver health and beyond.

Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

Cunesoft GmbH is a provider of cloud-based regulatory compliance software solutions tailored for the life sciences industry. Established in 2013 and headquartered in Munich, Germany, with offices in Princeton, New Jersey, and Bengaluru, India, Cunesoft offers a range of Software as a Service (SaaS) products. These include cune-IDMP, a master data management tool for accessing external regulatory databases; cune-eCTD, which facilitates electronic submission creation; and cune-Track, a workflow management system for regulatory tasks. Additionally, the company provides cune-RDMS for document navigation and tagging, cune-SOP for standard operating procedures, and cune-Portal for sharing regulatory documents. Cunesoft also offers outsourcing services for regulatory procedures and documentation. The company’s software is designed for quick deployment and is utilized by both small and medium-sized enterprises and larger pharmaceutical divisions globally, emphasizing reliability, security, and compliance. Cunesoft operates as a subsidiary of Phlexglobal Ltd. since January 2020.

iMusician Digital AG is a Swiss-based online platform established in 2007 that provides musicians with comprehensive tools to sell, manage, and monetize their music. The platform simplifies the digital music distribution process, allowing artists to sell and stream their music across major applications while maintaining control over their copyrights. iMusician enables users to track sales in real-time, ensuring they can effectively manage their earnings and protect their intellectual property. With a small, dedicated international team passionate about music, the company focuses on supporting artists so they can prioritize their creative work.

InSphero AG specializes in the development of organotypic biological 3D microtissues and microtissue-based assays, aimed at enhancing in vitro testing for drug discovery and toxicity assessment. Founded in 2009 and headquartered in Schlieren, Switzerland, the company provides a variety of products including liver, pancreas, and tumor microtissues, as well as custom-made microtissues and specialized kits. InSphero's 3D cell culture platforms, such as the GravityTRAP ultra-low attachment plate, facilitate the generation and analysis of scaffold-free 3D microtissue spheroids. Their offerings also extend to cytotoxicity assay kits and services for hepatotoxicity testing, cancer research, and stem cell applications. The technology developed by InSphero enables researchers to obtain biologically relevant insights, improving the predictive power of drug testing and reducing reliance on animal testing.

iMusician Digital AG is a Swiss-based online platform established in 2007 that provides musicians with comprehensive tools to sell, manage, and monetize their music. The platform simplifies the digital music distribution process, allowing artists to sell and stream their music across major applications while maintaining control over their copyrights. iMusician enables users to track sales in real-time, ensuring they can effectively manage their earnings and protect their intellectual property. With a small, dedicated international team passionate about music, the company focuses on supporting artists so they can prioritize their creative work.